Table 2.
Endpoints identified in health technology assessment reports.
| Categorya | Endpoint reported (% of category) N = 232 | |||
|---|---|---|---|---|
| Included in >1 cancer type | Malignant melanoma only | NSCLC only | RCC only | |
| Clinical response (n = 79) | Complete response (11%) Duration of response (13%) Objective response rate (13%) Overall response rate (12%) Partial response (10%) Objective tumor response (8%) Disease control rate (4%) Stable disease (4%) Time to response (3%) Response rates (1%) |
Disease progression (1%) Near complete response (1%) |
Tumor response (12%) Best tumor response (1%) Physical functioning (1%) Symptomatic improvement (1%) Time to tumor progression (1%) Time to worsening of patient reported outcomes (1%) Tolerance (1%) |
|
|
| ||||
| Disease progression (n = 65) | Progression-free survival (72%) Time to progression/progressive disease (15%) |
Time to treatment failure (8%) Time to worsening of symptoms (3%) |
Time to first event (2%) | |
|
| ||||
| Survival (n = 63) | Median OS (83%) 1-year survival (13%) 2-year survival (5%) |
|||
|
| ||||
| QoL (n = 25) | QoL (68%) Health-related QoL (20%) |
Disease-specific questionnaire (4%) Lung cancer symptom scale (4%) |
Patient reported outcomes (4%) | |
aHTA reports may include more than one endpoint category.